These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24329801)

  • 1. Hematopoietic stem cells for cancer immunotherapy.
    Gschweng E; De Oliveira S; Kohn DB
    Immunol Rev; 2014 Jan; 257(1):237-49. PubMed ID: 24329801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
    Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
    Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.
    Li YR; Zhou Y; Yu J; Zhu Y; Lee D; Zhu E; Li Z; Kim YJ; Zhou K; Fang Y; Lyu Z; Chen Y; Tian Y; Huang J; Cen X; Husman T; Cho JM; Hsiai T; Zhou JJ; Wang P; Puliafito BR; Larson SM; Yang L
    Mol Ther; 2024 Jun; 32(6):1849-1874. PubMed ID: 38584391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells.
    Stärck L; Popp K; Pircher H; Uckert W
    J Immunol; 2014 Jan; 192(1):206-13. PubMed ID: 24293634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.
    De Oliveira SN; Ryan C; Giannoni F; Hardee CL; Tremcinska I; Katebian B; Wherley J; Sahaghian A; Tu A; Grogan T; Elashoff D; Cooper LJ; Hollis RP; Kohn DB
    Hum Gene Ther; 2013 Oct; 24(10):824-39. PubMed ID: 23978226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns.
    Resetca D; Neschadim A; Medin JA
    J Immunother; 2016 Sep; 39(7):249-59. PubMed ID: 27488725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice.
    Gschweng EH; McCracken MN; Kaufman ML; Ho M; Hollis RP; Wang X; Saini N; Koya RC; Chodon T; Ribas A; Witte ON; Kohn DB
    Cancer Res; 2014 Sep; 74(18):5173-83. PubMed ID: 25038231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
    Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C
    Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
    Myburgh R; Kiefer JD; Russkamp NF; Magnani CF; Nuñez N; Simonis A; Pfister S; Wilk CM; McHugh D; Friemel J; Müller AM; Becher B; Münz C; van den Broek M; Neri D; Manz MG
    Leukemia; 2020 Oct; 34(10):2688-2703. PubMed ID: 32358567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
    Spranger S; Jeremias I; Wilde S; Leisegang M; Stärck L; Mosetter B; Uckert W; Heemskerk MH; Schendel DJ; Frankenberger B
    Blood; 2012 Apr; 119(15):3440-9. PubMed ID: 22371883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited transplantation of antigen-expressing hematopoietic stem cells induces long-lasting cytotoxic T cell responses.
    Denning WL; Xu J; Guo S; Klug CA; Hel Z
    PLoS One; 2011 Feb; 6(2):e16897. PubMed ID: 21379572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.
    Zhu Y; Smith DJ; Zhou Y; Li YR; Yu J; Lee D; Wang YC; Di Biase S; Wang X; Hardoy C; Ku J; Tsao T; Lin LJ; Pham AT; Moon H; McLaughlin J; Cheng D; Hollis RP; Campo-Fernandez B; Urbinati F; Wei L; Pang L; Rezek V; Berent-Maoz B; Macabali MH; Gjertson D; Wang X; Galic Z; Kitchen SG; An DS; Hu-Lieskovan S; Kaplan-Lefko PJ; De Oliveira SN; Seet CS; Larson SM; Forman SJ; Heath JR; Zack JA; Crooks GM; Radu CG; Ribas A; Kohn DB; Witte ON; Yang L
    Cell Stem Cell; 2019 Oct; 25(4):542-557.e9. PubMed ID: 31495780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.
    Li YR; Zhou Y; Kim YJ; Zhu Y; Ma F; Yu J; Wang YC; Chen X; Li Z; Zeng S; Wang X; Lee D; Ku J; Tsao T; Hardoy C; Huang J; Cheng D; Montel-Hagen A; Seet CS; Crooks GM; Larson SM; Sasine JP; Wang X; Pellegrini M; Ribas A; Kohn DB; Witte O; Wang P; Yang L
    Cell Rep Med; 2021 Nov; 2(11):100449. PubMed ID: 34841295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene-modified hematopoietic stem cells for cancer immunotherapy.
    Larson S; De Oliveira SN
    Hum Vaccin Immunother; 2014; 10(4):982-5. PubMed ID: 24398603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy.
    Kao RL; Truscott LC; Chiou TT; Tsai W; Wu AM; De Oliveira SN
    Hum Gene Ther; 2019 Apr; 30(4):413-428. PubMed ID: 30860401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.